Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	112.78	172.92	114.09	49.3	87.7	10.61
Short-Term Investments	533.28	483.71	84.1	187.26	22.41	-
Cash & Short-Term Investments	646.06	656.64	198.19	236.57	110.11	10.61
Cash Growth	88.34%	231.32%	-16.22%	114.85%	937.60%	653.16%
Other Current Assets	6.41	4.75	7.16	12.54	2.7	0.51
Total Current Assets	652.47	661.39	205.35	249.1	112.81	11.12
Net Property, Plant & Equipment	0.03	0.04	0.05	-	-	-
Long-Term Investments	-	-	-	2.48	-	-
Other Long-Term Assets	0.36	0.38	0.5	0.05	1.63	0
Total Assets	652.86	661.81	205.9	251.64	114.44	11.13
Accounts Payable	1.12	2.02	0.48	0.6	1.91	0.76
Accrued Expenses	13.6	13.1	14.17	9.88	6.16	4.29
Total Current Liabilities	14.72	15.11	14.65	10.48	8.07	5.05
Total Liabilities	14.72	15.11	14.65	10.48	8.07	5.05
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-in Capital	1,135	1,104	493.77	365.86	0.54	0.09
Retained Earnings	-496.51	-457.17	-302.52	-124.71	-52.81	-23.01
Total Common Shareholders' Equity	638.14	646.69	191.26	241.15	-52.27	-22.93
Minority Interest	-	-	-	-	158.64	29
Shareholders' Equity	638.14	646.69	191.26	241.15	106.38	6.07
Total Liabilities & Equity	652.86	661.81	205.9	251.64	114.44	11.13
Net Cash (Debt)	646.06	656.64	198.19	236.57	110.11	10.61
Net Cash Growth	-1.61%	231.32%	-16.22%	114.85%	937.60%	-
Net Cash Per Share	8.63	9.71	4.08	6.54	21.31	2.13
Book Value	638.14	646.69	191.26	241.15	-52.27	-22.93
Book Value Per Share	8.52	9.56	3.94	6.66	-10.12	-4.60
Tangible Book Value	638.14	646.69	191.26	241.15	-52.27	-22.93
Tangible Book Value Per Share	8.52	9.56	3.94	6.66	-10.12	-4.60

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q